The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis

Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2021-03, Vol.10 (5), p.925
Main Authors: Miyata, Yoichi, Kogure, Ryota, Nakazawa, Akiko, Nagata, Rihito, Mitsui, Tetsuya, Ninomiya, Riki, Komagome, Masahiko, Maki, Akira, Kawarabayashi, Nobuaki, Beck, Yoshifumi
Format: Article
Language:English
Subjects:
Bile ducts
Chemotherapy
Cholangiocarcinoma
Clinical medicine
Gallbladder
Gastric cancer
Hepatectomy
Lymphatic system
Medical prognosis
Metastasis
Pancreatic cancer
Pancreaticoduodenectomy
Patients
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, = 0.033; OS, not available vs. 28.2 months, = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion ( < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10050925